Adamis Pharmaceuticals Corporation (ADMP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

0.3703

-0.0046

(-1.23%)

At close: 04:00PM EDT

0.3706

+0.00

(+0.08%)

After hours:

04:49PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Fast Stochastic

View all chart patterns

Performance Outlook

Previous Close	0.3749
Open	0.3700
Bid	0.3700 x 4000
Ask	0.3846 x 1400
Day's Range	0.3675 - 0.3951
52 Week Range	0.3100 - 1.4800
Volume	793,683
Avg. Volume	607,141

Market Cap	55.539M
Beta (5Y Monthly)	1.00
PE Ratio (TTM)	N/A
EPS (TTM)	-0.2730
Earnings Date	Aug 10, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	0.42

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADMP

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Adamis Pharmaceuticals Corporat
Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
Rating
Fair Value
Economic Moat
yesterdayMorningstar

All

GlobeNewswire
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Wednesday, August 10, 2022 at 1:30 p.m. Pacific Time to discuss its financial and operating results for the second quarter 2022 as well as provide a corporate update. The company’s press releas
- LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2022 Results on August 23, 2022
  GlobeNewswire
- Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
  Business Wire
GlobeNewswire
Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
ISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote (or Change Their Vote) is 11:59 p.m. PT on August 11, 2022 SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended the Company’s stockholders vote FOR Proposal #2 and Proposal #3
GlobeNewswire
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Interim DSMB review expected in late SeptemberSAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19. The next Data Safety Monitoring Board (DSMB) meeting to review interim data results has been scheduled for late September. The DSMB previously met to evaluate the clinical and safety data from interim ana